You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
春立醫療(01858.HK)中期淨利潤增加33%至1.56億元
格隆匯 08-06 19:45

格隆匯8月6日丨春立醫療(01858.HK)公吿,截至2021年6月30日止6個月,公司營業收入增長18.57%至人民幣4.83億元,主要是由於關節假體產品銷量的增長所致。期間毛利增長37.56%至約人民幣3.96億元;淨利潤增加33%至約人民幣1.56億元,淨利潤的增長主要來自於公司收入的增長。

毛利率由截至2020年6月30日止六個月的70.79%上升到截至2021年6月30日止六個月的76.51%,主要是由於1)兩票制地區銷售收入佔比上升所致;2)公司量產導致固定成本相對下降;3)外協噴塗廠商採購價格有所下降,外協成本逐步減少所致;4)部分鈷毛坯、鈦毛坯等主要原材料陸續由外採改為自產導致本公司材料成本下降所致。

公司的研發費用由截至2020年6月30日止六個月的約人民幣3160萬元上升至截至2021年6月30日止六個月的約人民幣3420萬元,公司的2021年上半年研發費用佔收入的比例為7.08%。主要是由於公司重視新產品、新技術、新工藝的研發,持續加大研發項目論證、研發人員薪酬等相關費用投入增加所致。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account